Physician profile
Jamie Rhoads
NPI 1104093392
$104,615.21
in general payments reported to CMS, 2019-2025
14 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $89.95 · 2021: $579 · 2022: $41K · 2023: $28K · 2024: $4,140 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $7,977 · Food and Beverage: $773 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,100.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,899.70 |
| Travel and Lodging | $7,977.44 |
| Food and Beverage | $772.52 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48,236.65 | 2021-2023 | Olumiant, Taltz |
| Regeneron Pharmaceuticals, INC. | $32,046.18 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,739.29 | 2022-2024 | Spevigo |
| Argenx US, INC. | $7,560.41 | 2022-2024 | Vyvgart |
| Eli Lilly and Company | $2,500.00 | 2022 | |
| Janssen Biotech, INC. | $353.93 | 2020-2025 | Tremfya |
| Abbvie INC. | $165.20 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $13.55 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Rhoads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.